Non-alcoholic Fatty Liver Disease (NAFLD) Clinical Trial
Official title:
Comparison of Steatosis and Fibrosis Measurements From Velacur and MRE/MRI-PDFF in Patients With Chronic Liver Disease
The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD). The main aims is to: - Validate the use of Velacur and elastography cut offs in a patient cohort with all types of chronic liver disease, against MRE results for fibrosis staging. - Validate the use of Velacur and attenuation cut offs in a patient cohort with all types of chronic liver disease, against MRI-PDFF results for steatosis staging. Participants will Study participants will attend 1 study visit, in which measurement of liver stiffness with Velacur and FibroScan, will be performed by a certified technician. As part of Visit 1, Patients will also complete an MRI exam which will include both MRE and MRI-PDFF measurements (MRI imaging can take place within 28 days of the Velacur scan).
This will be a prospective, open label, validation study of the Velacur system in comparison to MRE and MRI-PDFF in patients with liver disease or suspected liver disease. Approximately 100 subjects may be enrolled in this study. Participants should span all levels of fibrosis and steatosis. The study is comprised of: Screening Period (up to 8 days) and Visit 1. There are no safety follow-up visits in this study. The primary objective of the study is to compare the results of Velacur against MRE and MRI-PDFF results for liver stiffness and steatosis. As part of prior studies, using MRE as the gold standard, clinical cut-off for Velacur have been developed. The primary objective of this study is to validate these cut-offs to see if Velacur can correctly classify patients. Secondary objectives include correlating the stiffness and attenuation results of Velacur with other clinical measures of fibrosis and steatosis such as Fib-4, and correlations with other clinical measurements collected through clinical care or clinical trials, such as Enhance Liver Fibrosis (ELF) test, FibroScan, MRI, or ultrasound based shear wave elastography (SWE) as they are available. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04099147 -
Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence.
|
||
| Completed |
NCT04019561 -
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
|
Phase 2 | |
| Withdrawn |
NCT00375349 -
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
|
N/A | |
| Active, not recruiting |
NCT04682600 -
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
|
N/A | |
| Terminated |
NCT02605616 -
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 2 | |
| Completed |
NCT04165343 -
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
|
||
| Recruiting |
NCT03151473 -
Longitudinal Observational Study Of Chinese With NAFLD/NASH
|
||
| Recruiting |
NCT04820036 -
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
|
N/A | |
| Active, not recruiting |
NCT02037321 -
Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk
|
N/A | |
| Completed |
NCT01997424 -
Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
|
N/A | |
| Completed |
NCT01110577 -
Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)
|
N/A | |
| Completed |
NCT00771108 -
Exercise Dose and Nonalcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT04639414 -
Combined Active Treatment in Type 2 Diabetes With NASH
|
Phase 4 | |
| Completed |
NCT04450875 -
Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD
|
N/A | |
| Recruiting |
NCT02654665 -
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
|
Phase 3 | |
| Recruiting |
NCT05699018 -
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
|
N/A | |
| Withdrawn |
NCT02457286 -
Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
|
Phase 1 | |
| Withdrawn |
NCT02194894 -
The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
|
N/A | |
| Completed |
NCT01811472 -
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
|
Phase 2 | |
| Completed |
NCT00968747 -
Regulation of FGF21 by Nutritional Challenges
|
N/A |